Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.255
-0.035 (-1.53%)
Mar 9, 2026, 3:10 PM EDT - Market open
Xenetic Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 2.86 | 2.5 | 2.54 | 1.71 | 1.16 | 0.44 | Upgrade
|
| Revenue Growth (YoY) | 13.30% | -1.56% | 48.80% | 47.06% | 165.64% | 2460.31% | Upgrade
|
| Gross Profit | 2.86 | 2.5 | 2.54 | 1.71 | 1.16 | 0.44 | Upgrade
|
| Selling, General & Admin | 2.84 | 3.42 | 3.56 | 3.65 | 3.74 | 3.4 | Upgrade
|
| Research & Development | 3.33 | 3.29 | 3.49 | 4.77 | 3.16 | 1.73 | Upgrade
|
| Operating Expenses | 6.17 | 6.7 | 7.06 | 8.42 | 6.91 | 5.13 | Upgrade
|
| Operating Income | -3.31 | -4.2 | -4.52 | -6.72 | -5.75 | -4.69 | Upgrade
|
| Interest & Investment Income | 0.16 | 0.25 | 0.36 | 0.17 | 0.1 | 0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0.01 | 0.03 | -0 | 0 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -3.16 | -3.96 | -4.13 | -6.55 | -5.65 | -4.57 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -9.24 | Upgrade
|
| Pretax Income | -3.16 | -3.96 | -4.13 | -6.55 | -5.65 | -13.81 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | -2.92 | Upgrade
|
| Net Income | -3.16 | -3.96 | -4.13 | -6.55 | -5.65 | -10.89 | Upgrade
|
| Net Income to Common | -3.16 | -3.96 | -4.13 | -6.55 | -5.65 | -10.89 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 2 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 0.11% | 0.86% | 7.44% | 38.38% | 60.81% | 124.10% | Upgrade
|
| EPS (Basic) | -2.05 | -2.57 | -2.71 | -4.61 | -5.49 | -17.04 | Upgrade
|
| EPS (Diluted) | -2.05 | -2.57 | -2.71 | -4.61 | -5.49 | -17.04 | Upgrade
|
| Free Cash Flow | -2.72 | -2.82 | -4.11 | -4.65 | -4.74 | -4.27 | Upgrade
|
| Free Cash Flow Per Share | -1.76 | -1.83 | -2.69 | -3.27 | -4.61 | -6.67 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -115.80% | -168.16% | -177.78% | -393.57% | -495.12% | -1074.41% | Upgrade
|
| Profit Margin | -110.40% | -158.39% | -162.78% | -383.87% | -486.36% | -2493.11% | Upgrade
|
| Free Cash Flow Margin | -95.07% | -112.69% | -161.98% | -272.23% | -408.21% | -976.60% | Upgrade
|
| EBITDA | - | - | - | - | -5.75 | -4.69 | Upgrade
|
| D&A For EBITDA | - | - | - | - | 0 | 0 | Upgrade
|
| EBIT | -3.31 | -4.2 | -4.52 | -6.72 | -5.75 | -4.69 | Upgrade
|
| EBIT Margin | -115.80% | -168.16% | -177.78% | - | - | - | Upgrade
|
| Revenue as Reported | 2.86 | 2.5 | 2.54 | 1.71 | 1.16 | 0.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.